RecentMedicalFindings.com
Summarizing relevant biomedical research!
mast cell sarcoma     Bookmark and Share
Search webpages of this site (RecentMedicalFindings):
Didn't find what you wanted? Try it at BioMedLib™ !
Search directly on the biomedical articles using BioMedLib™ search engine:



1. Biomedical articles (top 50; 2009 to 2014)
1. |||||||||. 100%  Fujimoto A, Wada Y, Kanada T, Ishikawa Y, Kadota K: Mast cell sarcoma with megakaryocytic differentiation in a calf. J Vet Med Sci; 2012 Dec;74(12):1643-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell sarcoma with megakaryocytic differentiation in a calf.
  • A case of mast cell sarcoma in a 5-month-old Holstein female calf is described.
  • Macroscopically, enlargement of the spleen, lymph nodes, tonsils and kidneys was noted, and there were tumor masses in the neck region and on the pleura and peritoneum.
  • The pericardium and uterine and ureter walls were also involved by tumor.
  • Some of the predominant type of these tumor cells were found within the epithelia of the lungs, tonsils, gastrointestinal tract, liver, ureters, urinary bladder and uterus.
  • [MeSH-major] Cattle Diseases / pathology. Mast-Cell Sarcoma / veterinary. Megakaryocytes / pathology. Tumor Markers, Biological / metabolism

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22813945.001).
  • [ISSN] 1347-7439
  • [Journal-full-title] The Journal of veterinary medical science / the Japanese Society of Veterinary Science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Naphthols; 0 / Tumor Markers, Biological; 35245-26-2 / naphthol AS-D chloroacetate; 9001-27-8 / Factor VIII; EC 3.1.- / Esterases; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


2. |||||||||. 97%  Ryan RJ, Akin C, Castells M, Wills M, Selig MK, Nielsen GP, Ferry JA, Hornick JL: Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications. Mod Pathol; 2013 Apr;26(4):533-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications.
  • Mast cell sarcoma is a rare, aggressive neoplasm composed of cytologically malignant mast cells presenting as a solitary mass.
  • Previous descriptions of mast cell sarcoma have been limited to single case reports, and the pathologic features of this entity are not well known.
  • Here, we report three new cases of mast cell sarcoma and review previously reported cases.
  • Mast cell sarcoma has a characteristic morphology of medium-sized to large epithelioid cells, including bizarre multinucleated cells, and does not closely resemble either normal mast cells or the spindle cells of systemic mastocytosis.
  • None of our three cases were correctly diagnosed as mast cell neoplasms on initial pathological evaluation, suggesting that this entity may be under-recognized.
  • Molecular testing of mast cell sarcoma has not thus far detected the imatinib-resistant KIT D816V mutation, suggesting that recognition of these cases may facilitate specific targeted therapy.
  • [MeSH-major] Mast-Cell Sarcoma / pathology

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23196796.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. |......... 4%  Bautista-Quach MA, Ake CD, Chen M, Wang J: Gastrointestinal lymphomas: Morphology, immunophenotype and molecular features. J Gastrointest Oncol; 2012 Sep;3(3):209-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of these, the two most frequently encountered histologic subtypes are extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), where Helicobacter pylori infection is implicated in a number of cases, and diffuse large B cell lymphoma.
  • Several B cell lymphomas are associated with chromosomal aberrations.
  • Enteropathy-associated T cell lymphoma, type I in particular, usually arises in a background of celiac disease.
  • T cell gene rearrangement confirms clonality.
  • NK/T cell neoplasms are invariably associated with Epstein-Barr virus infection and are often aggressive; thus, differentiation from a benign NK-cell enteropathy is paramount.
  • Although incidence of other hematopoietic malignancies in the gastrointestinal tract such as plasma cell myeloma associated with amyloidosis, plasmablastic lymphoma, Hodgkin disease, histiocytic sarcoma and mast cell sarcoma is extremely rare, these entities have been documented, with the latter two demonstrating aggressive clinical behavior.
  • Endoscopic ultrasonography is an important adjunct in disease staging and follow-up.
  • Conservative antibiotic treatment of stage I MALT lymphomas with associated Helicobacter pylori infection achieves good clinical outcome with high remission rate.

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2009 Dec 7;15(45):5746-50 [19960575.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1133-44 [15316312.001]
  • [Cites] Clin Gastroenterol Hepatol. 2010 Oct;8(10):A20 [20601139.001]
  • [Cites] Blood. 2011 Feb 3;117(5):1447-52 [20966166.001]
  • [Cites] J Cancer Res Ther. 2010 Jul-Sep;6(3):342-3 [21119271.001]
  • [Cites] Mediterr J Hematol Infect Dis. 2009;1(2):e2009030 [21416007.001]
  • [Cites] Am J Surg Pathol. 2011 Aug;35(8):1195-203 [21716086.001]
  • [Cites] Am J Surg Pathol. 2011 Sep;35(9):1255-63 [21836483.001]
  • [Cites] Pediatr Surg Int. 2012 Mar;28(3):267-70 [21969235.001]
  • [Cites] Srp Arh Celok Lek. 2011 Jul-Aug;139(7-8):523-6 [21980666.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1285-8 [15492998.001]
  • [Cites] Mod Pathol. 2005 May;18(5):693-704 [15696128.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6370-8 [16155022.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1345-53 [16174856.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1274-80 [17001159.001]
  • [Cites] Leukemia. 2007 Mar;21(3):389-96 [17230229.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5124-32 [17785567.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):776-87 [18076735.001]
  • [Cites] Curr Opin Gastroenterol. 2008 Sep;24(5):623-6 [19122505.001]
  • [Cites] Minerva Chir. 2009 Apr;64(2):229-33 [19365324.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2009 Mar;17(2):172-7 [19521280.001]
  • [Cites] Korean J Gastroenterol. 2009 Sep;54(3):174-9 [19844154.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2010 Feb;24(1):27-34 [20206106.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2010 Feb;24(1):43-56 [20206108.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2010 Feb;24(1):71-7 [20206110.001]
  • [Cites] J Clin Invest. 2010 Jun;120(6):2131-43 [20440074.001]
  • [Cites] J Gastrointest Cancer. 2012 Jun;43(2):379-81 [20703830.001]
  • [Cites] Histopathology. 2011 Jan;58(1):49-68 [21261683.001]
  • [Cites] J Immunol. 2011 Jun 1;186(11):6165-72 [21518972.001]
  • [Cites] J Clin Pathol. 2011 Nov;64(11):1035-7 [21778298.001]
  • [Cites] Virchows Arch. 2011 Nov;459(5):495-502 [22002677.001]
  • [Cites] Pathol Res Pract. 2011 Dec 15;207(12):786-9 [22078056.001]
  • [Cites] Acta Gastroenterol Belg. 2011 Sep;74(3):451-3 [22103053.001]
  • [Cites] Mod Pathol. 1999 Jul;12(7):739-43 [10430280.001]
  • [Cites] Am J Gastroenterol. 2002 Feb;97(2):292-7 [11866264.001]
  • [Cites] Gut. 2002 May;50 Suppl 3:III19-24 [11953328.001]
  • [Cites] Surg Endosc. 2003 Mar;17(3):469-74 [12404054.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):623-9 [12649111.001]
  • [Cites] Pathol Res Pract. 2004;200(6):473-8 [15310151.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Nov;44(3):247-55 [16049916.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Ann Hematol. 2006 Dec;85(12):849-56 [16944146.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):310-9 [17277765.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):65-71 [17339119.001]
  • [Cites] Diagn Pathol. 2012;7:16 [22333190.001]
  • [Cites] J Gastroenterol Hepatol. 2012 Mar;27(3):617 [22353350.001]
  • [Cites] Am J Gastroenterol. 2008 Jan;103(1):62-70 [17894851.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):1992-9 [18647965.001]
  • [Cites] Surg Endosc. 2009 Oct;23(10):2191-6 [19118429.001]
  • [Cites] Leuk Lymphoma. 2009 Mar;50(3):335-40 [19255922.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2009;23(5):671-8 [19744632.001]
  • [Cites] Gastrointest Endosc. 2010 Mar;71(3):655-7 [19879569.001]
  • [Cites] Blood. 2011 Dec 1;118(23):6018-22 [21984805.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):216-24 [11812943.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):586-91 [12548600.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):730-45 [12949719.001]
  • [Cites] J Gastroenterol. 2003;38(10):921-9 [14614598.001]
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):239-48 [14724303.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):28-37 [15213615.001]
  • [Cites] Gastrointest Endosc. 2010 Apr;71(4):851-5 [20363431.001]
  • (PMID = 22943012.001).
  • [ISSN] 2219-679X
  • [Journal-full-title] Journal of gastrointestinal oncology
  • [ISO-abbreviation] J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3418529
  • [Keywords] NOTNLM ; Gastrointestinal lymphomas / MALT lymphoma / NK/T-cell enteropathy
  •  go-up   go-down


Advertisement
4. |......... 2%  Monteiro B, Boston S, Monteith G: Factors influencing complete tumor excision of mast cell tumors and soft tissue sarcomas: a retrospective study in 100 dogs. Can Vet J; 2011 Nov;52(11):1209-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing complete tumor excision of mast cell tumors and soft tissue sarcomas: a retrospective study in 100 dogs.
  • The recommended treatment for soft tissue sarcomas (STS) and mast cell tumors (MCT) is complete surgical removal, provided that the tumor is amenable to surgical excision.
  • Decreased body weight was a risk factor (P = 0.03, odd's ratio = 0.96) as well as increased tumor size (1.4% increase in risk of incomplete excision per cm(2); P = 0.02).
  • Gender, age, breed, location, grade, tumor type, re-excision, and level of surgeon's training (P = 0.0711) were not significant.
  • [MeSH-major] Dog Diseases / surgery. Mast-Cell Sarcoma / veterinary. Sarcoma / veterinary

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bull World Health Organ. 1974;50(1-2):79-100 [4547652.001]
  • [Cites] Aust Vet J. 1979 Dec;55(12):602-4 [231964.001]
  • [Cites] J Bone Joint Surg Am. 1989 Mar;71(3):370-5 [2925710.001]
  • [Cites] Semin Vet Med Surg (Small Anim). 1986 Feb;1(1):72-83 [3148990.001]
  • [Cites] J Am Vet Med Assoc. 1992 Sep 15;201(6):873-8 [1383179.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):473-8 [8636760.001]
  • [Cites] J Am Vet Med Assoc. 1997 Nov 1;211(9):1147-51 [9364229.001]
  • [Cites] J Am Vet Med Assoc. 2005 Apr 15;226(8):1368-74 [15844431.001]
  • [Cites] J Vet Diagn Invest. 2005 May;17(3):245-8 [15945380.001]
  • [Cites] J Am Anim Hosp Assoc. 2005 Jul-Aug;41(4):241-6 [15995161.001]
  • [Cites] J Am Vet Med Assoc. 2005 Nov 1;227(9):1442-8 [16279389.001]
  • [Cites] J Am Vet Med Assoc. 2006 Jan 1;228(1):91-5 [16426175.001]
  • [Cites] J Am Vet Med Assoc. 2006 Jan 15;228(2):210-5 [16426187.001]
  • [Cites] J Am Vet Med Assoc. 2007 Feb 15;230(4):548-54 [17302554.001]
  • [Cites] Vet Pathol. 2007 May;44(3):335-41 [17491075.001]
  • [Cites] J Small Anim Pract. 2007 Aug;48(8):424-31 [17559522.001]
  • [Cites] Jpn J Clin Oncol. 2008 Oct;38(10):701-9 [18845523.001]
  • [Cites] Vet Surg. 2008 Jul;37(5):461-5 [18986313.001]
  • [Cites] J Vet Intern Med. 2008 Nov-Dec;22(6):1373-9 [18976288.001]
  • [Cites] Vet Pathol. 2009 Mar;46(2):362-4, author reply 364-5 [19261652.001]
  • [Cites] Vet Pathol. 2009 Sep;46(5):928-33 [19429989.001]
  • [Cites] J Am Vet Med Assoc. 2000 Jul 15;217(2):205-10 [10909459.001]
  • [Cites] J Am Vet Med Assoc. 2001 Apr 1;218(7):1120-3 [11318363.001]
  • [Cites] J Am Anim Hosp Assoc. 2002 Jan-Feb;38(1):71-3 [11804319.001]
  • [Cites] J Vet Med A Physiol Pathol Clin Med. 2002 Mar;49(2):87-91 [11958472.001]
  • [Cites] J Am Anim Hosp Assoc. 2002 Sep-Oct;38(5):458-66 [12220031.001]
  • [Cites] J Am Vet Med Assoc. 2004 Jan 15;224(2):236-40 [14736068.001]
  • [Cites] Aust Vet J. 2003 Dec;81(12):732-8 [15080482.001]
  • [Cites] Vet Rec. 2004 Jun 12;154(24):743-6 [15224593.001]
  • [Cites] J Small Anim Pract. 1973 Jan;14(1):27-41 [4199921.001]
  • [Cites] Cancer Res. 1974 Nov;34(11):2859-68 [4529096.001]
  • [Cites] Vet Pathol. 1984 Sep;21(5):469-74 [6435301.001]
  • [Cites] Aust Vet J. 1987 Jun;64(6):161-4 [3115242.001]
  • (PMID = 22547841.001).
  • [ISSN] 0008-5286
  • [Journal-full-title] The Canadian veterinary journal. La revue vétérinaire canadienne
  • [ISO-abbreviation] Can. Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3196013
  •  go-up   go-down


5. |......... 1%  Carlsten KS, London CA, Haney S, Burnett R, Avery AC, Thamm DH: Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors. J Vet Intern Med; 2012 Jan-Feb;26(1):135-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.
  • BACKGROUND: Mast cell tumors (MCT) are common cutaneous tumors in dogs and when not amenable to surgical excision can present a therapeutic challenge.
  • METHODS: Prospective clinical trial.
  • CONCLUSIONS AND CLINICAL IMPORTANCE: The combination of hypofractionated RT, toceranib, and prednisone was tolerated and efficacious in the majority of dogs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dog Diseases / drug therapy. Dog Diseases / radiotherapy. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Disease-Free Survival. Dogs. Female. Indoles / administration & dosage. Kaplan-Meier Estimate. Male. Polymerase Chain Reaction / veterinary. Prednisone / administration & dosage. Prospective Studies. Proto-Oncogene Proteins c-kit / genetics. Pyrroles / administration & dosage

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • HSDB. structure - PYRROLE.
  • HSDB. structure - PREDNISONE.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 by the American College of Veterinary Internal Medicine.
  • [Cites] Eur J Cancer. 2008 Nov;44(16):2506-17 [18723339.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] Clin Cancer Res. 2009 Jun 1;15(11):3856-65 [19470739.001]
  • [Cites] Vet Anaesth Analg. 2008 Jul;35(4):355-62 [18466168.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1207-16 [19545786.001]
  • [Cites] Cancer. 2009 Aug 1;115(15):3571-80 [19536893.001]
  • [Cites] J Radiat Res. 2004 Dec;45(4):557-61 [15635266.001]
  • [Cites] Neoplasia. 2006 Feb;8(2):104-11 [16611403.001]
  • [Cites] Vet Pathol. 2007 May;44(3):298-308 [17491070.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):873-9 [18514780.001]
  • [Cites] Top Companion Anim Med. 2009 Aug;24(3):106-12 [19732728.001]
  • [Cites] J Vet Pharmacol Ther. 2010 Apr;33(2):162-71 [20444041.001]
  • [Cites] Am J Vet Res. 2002 Dec;63(12):1718-23 [12492288.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2755-68 [12855656.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4009-16 [12873999.001]
  • [Cites] Adv Vet Sci Comp Med. 1970;14:309-54 [4922146.001]
  • [Cites] J Am Vet Med Assoc. 1970 Dec 1;157(11):1707-12 [4991973.001]
  • [Cites] Vet Clin North Am. 1974 Nov;4(4):889-96 [4216135.001]
  • [Cites] J Natl Cancer Inst. 1979 Sep;63(3):691-4 [112313.001]
  • [Cites] Br Vet J. 1986 Jan-Feb;142(1):1-19 [3947927.001]
  • [Cites] J Am Vet Med Assoc. 1988 Oct 15;193(8):936-40 [3142828.001]
  • [Cites] J Vet Intern Med. 1994 Nov-Dec;8(6):406-8 [7884726.001]
  • [Cites] Cornell Vet. 1964 Oct;54:517-9 [14234055.001]
  • (PMID = 22176473.001).
  • [ISSN] 1939-1676
  • [Journal-full-title] Journal of veterinary internal medicine / American College of Veterinary Internal Medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016058; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NCATS NIH HHS / TR / UL1 TR000090
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Indoles; 0 / Pyrroles; 24F9PF7J3R / toceranib phosphate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ NIHMS522752; NLM/ PMC3837098
  •  go-up   go-down


6. |......... 1%  Vail DM, von Euler H, Rusk AW, Barber L, Clifford C, Elmslie R, Fulton L, Hirschberger J, Klein M, London C, Martano M, McNiel EA, Morris JS, Northrup N, Phillips B, Polton G, Post G, Rosenberg M, Ruslander D, Sahora A, Siegel S, Thamm D, Westberg S, Winter J, Khanna C: A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs. J Vet Intern Med; 2012 May-Jun;26(3):598-607
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs.
  • BACKGROUND: Effective treatments for dogs with advanced stage mast cell tumors (MCT) remain a pressing need.
  • METHODS: Prospective multicenter randomized double-blind positive-controlled clinical trial.
  • CONCLUSIONS AND CLINICAL IMPORTANCE: Paclitaxel (micellar)'s activity and safety profile are superior to lomustine.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Dog Diseases / drug therapy. Mast-Cell Sarcoma / veterinary. Micelles. Paclitaxel / therapeutic use

  • HSDB. structure - TAXOL.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2012 by the American College of Veterinary Internal Medicine.
  • [Cites] J Vet Intern Med. 1999 Nov-Dec;13(6):601-5 [10587263.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Am J Vet Res. 2002 Dec;63(12):1718-23 [12492288.001]
  • [Cites] J Am Anim Hosp Assoc. 2004 Mar-Apr;40(2):124-30 [15007048.001]
  • [Cites] J Vet Intern Med. 2004 Mar-Apr;18(2):219-22 [15058774.001]
  • [Cites] Vet Pathol. 1984 Sep;21(5):469-74 [6435301.001]
  • [Cites] J Vet Intern Med. 1999 Sep-Oct;13(5):491-7 [10499735.001]
  • [Cites] J Vet Med Sci. 2006 Jun;68(6):581-7 [16820715.001]
  • [Cites] Am J Vet Res. 2007 Nov;68(11):1246-51 [17975981.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1137-45 [18644978.001]
  • [Cites] J Vet Intern Med. 2008 Nov-Dec;22(6):1390-6 [19000249.001]
  • [Cites] J Vet Intern Med. 2008 Nov-Dec;22(6):1301-9 [18823406.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] Vet Comp Oncol. 2008 Jun;6(2):111-9 [19178670.001]
  • [Cites] Clin Cancer Res. 2009 Jun 1;15(11):3856-65 [19470739.001]
  • [Cites] Vet Comp Oncol. 2010 Jun;8(2):138-52 [20579327.001]
  • [Cites] J Vet Intern Med. 2010 Nov-Dec;24(6):1452-7 [21039869.001]
  • [Cites] J Vet Intern Med. 2011 Jul-Aug;25(4):838-45 [21689156.001]
  • [Cites] Vet Comp Oncol. 2013 Dec;11(4):243-55 [22404965.001]
  • (PMID = 22390318.001).
  • [ISSN] 1939-1676
  • [Journal-full-title] Journal of veterinary internal medicine / American College of Veterinary Internal Medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016058; United States / NCATS NIH HHS / TR / UL1 TR000090
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Micelles; 33069-62-4 / Paclitaxel
  • [Other-IDs] NLM/ NIHMS462480; NLM/ PMC3837094
  •  go-up   go-down


7. |......... 3%  Cooper IF, Siadaty MS: 'Cells' associated with 'Body Of Uterus Sarcoma': Top Publications. BioMedLib Review; Cell;BodyOfUterus:706132852. ISSN: 2331-5717. 2014/6/23
PDF icon [Fulltext service] Download fulltext PDF of this article.

  • [Title] 'Cells' associated with 'Body Of Uterus Sarcoma': Top Publications.
  • There are articles published each month which present 'Cell' for 'body of uterus sarcoma'.
  • Murali Krishna C et al: Characterisation of uterine sarcoma cell lines exhibiting MDR phenotype by vibrational spectroscopy.
  • Greer DA et al: Distinct N-glycan glycosylation of P-glycoprotein isolated from the human uterine sarcoma cell line MES-SA/Dx5.
  • Kim SC et al: Successful treatment of a granulocytic sarcoma of the uterine cervix in complete remission at six-year follow-up.
  • Coley HM et al: Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines.
  • Risinger JI et al: Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity.
  • Zhu XQ et al: [Mast cells in cellular leiomyoma and endometrial stromal sarcoma of the uterus].
  • Vollmer G et al: Localization of tenascin in uterine sarcomas and partially transformed endometrial stromal cells.
  • Roomi MW et al: Anticancer effects of a specific mixture of nutrients in the multidrug-resistant human uterine sarcoma MES-SA/Dx5 and the drug-sensitive MES-SA cell lines.
  • Ma HB et al: Successful treatment of mast cell sarcoma of the uterus with imatinib.
  • Sanyal C: Stromal cell sarcoma of uterus in a teenaged girl.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2014 Siadaty and Cooper; licensee BioMedLib LLC.
  • (UID = 706132852.001).
  • [ISSN] 2331-5717
  • [Journal-full-title] BioMedLib Review
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] UNITED STATES
  •  go-up   go-down


8. |......... 3%  Cooper IF, Siadaty MS: 'Steroids' associated with 'Sarcoma Of Tibia': Top Publications. BioMedLib Review; Steroid;SarcomaOfTibia:705763075. ISSN: 2331-5717. 2014/4/27
PDF icon [Fulltext service] Download fulltext PDF of this article.

  • [Title] 'Steroids' associated with 'Sarcoma Of Tibia': Top Publications.
  • Background: There are articles published each month which present 'steroid' for 'sarcoma of tibia'.
  • Finding such articles is important for researchers, clinicians, and patients.
  • In group one there are publications with the strongest evidence of association. We focused finding the most relevant publications pertinent to our goal, rather than combining them into a conclusion section. Such textual synthesis will be the focus of our next project.
  • Brcić L et al: Mast-cell sarcoma of the tibia.
  • Beck SE et al: Intraosseous synovial sarcoma of the proximal tibia.
  • Kashima TG et al: Localized Ewing sarcoma of the tibia.
  • Ramseier LE et al: Allograft reconstruction for bone sarcoma of the tibia in the growing child.
  • Ozaki T et al: Reconstruction with ipsilateral fibula transfer with pasteurized bone after excision of bone sarcoma of the tibia.
  • Arkader A et al: Ewing sarcoma of the tibia mimicking fibrous dysplasia.
  • Kenan S et al: Case report 819: Periosteal Ewing's sarcoma of the tibia.
  • Ogihara Y et al: Limb salvage for bone sarcoma of the proximal tibia.
  • Agarwal N et al: Ewing's sarcoma of the calcaneus with metastases to the tibia and fibula.
  • Milgrom C et al: MRI and CT scan compared with microscopic histopathology in osteogenic sarcoma of the proximal tibia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2014 Siadaty and Cooper; licensee BioMedLib LLC.
  • (UID = 705763075.001).
  • [ISSN] 2331-5717
  • [Journal-full-title] BioMedLib Review
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] UNITED STATES
  •  go-up   go-down


9. |||||||||. 117%  Weiler CR, Butterfield J: Mast cell sarcoma: clinical management. Immunol Allergy Clin North Am; 2014 May;34(2):423-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell sarcoma: clinical management.
  • Mast cell sarcoma is a disorder that results in abnormal mast cells as identified by morphology, special stains, and in some publications, c-kit mutation analysis.
  • In humans it is a very rare condition, with variable clinical presentation.
  • There is no standard therapy for the disorder.
  • The prognosis of mast cell sarcoma in published literature is very poor in humans.

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2014 Elsevier Inc. All rights reserved.
  • (PMID = 24745684.001).
  • [ISSN] 1557-8607
  • [Journal-full-title] Immunology and allergy clinics of North America
  • [ISO-abbreviation] Immunol Allergy Clin North Am
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Clinical presentation of mast cell sarcoma / Mast cell sarcoma / Mastocytosis / Prognosis of mast cell sarcoma / Treatment of mast cell sarcoma
  •  go-up   go-down


10. |||||||||. 116%  Falleti J, Borgia L, Lalinga AV, De Cecio R, Natella V, Patitucci G, Vita G: Mast cell sarcoma of the scalp: the first sign of undisclosed systemic mastocytosis? Pathol Res Pract; 2012 Nov 15;208(11):683-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell sarcoma of the scalp: the first sign of undisclosed systemic mastocytosis?
  • Mastocytosis is a neoplastic disease of mast cells and their CD34+ precursors, including a heterogeneous group of disorders.
  • It is characterized by abnormal growth and accumulation of mast cells in one or more organ systems.
  • Mast cell sarcoma is an extremely rare and aggressive disease characterized by local proliferation of atypical mast cells, destructive growth and poor prognosis, without systemic involvement.
  • Very few clinical cases describing this entity have been reported in the literature.
  • In this paper, we report a case of a mast cell sarcoma, localized in the scalp of a 63-year-old woman; it appears to be the first manifestation of undisclosed systemic mastocytosis.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Mast Cells / pathology. Mast-Cell Sarcoma / diagnosis. Mastocytosis, Systemic / diagnosis. Scalp. Skin Neoplasms / diagnosis
  • [MeSH-minor] DNA Mutational Analysis. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Humans. Middle Aged. Mutation. Proto-Oncogene Proteins c-kit / genetics. Proto-Oncogene Proteins c-kit / metabolism. Tumor Markers, Biological / metabolism

  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Systemic mastocytosis.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2012 Elsevier GmbH. All rights reserved.
  • (PMID = 22963840.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Tumor Markers, Biological; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


11. |||||||||. 106%  Ma HB, Xu X, Liu WP, Chang H, Zeng F, Wang YC: Successful treatment of mast cell sarcoma of the uterus with imatinib. Int J Hematol; 2011 Nov;94(5):491-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of mast cell sarcoma of the uterus with imatinib.
  • Mast cell sarcoma is a rare disease characterized by localized, but destructive and rapid, growth of the tumor, high risk of distant metastasis, possibility of a leukemic phase, and poor prognosis.
  • We report successful treatment of uterine mast cell sarcoma with imatinib in a 39-year-old woman who presented with abdominal distention and massive ascites.
  • We administered imatinib to the patient and achieved a good response in the absence of c-kit mutation, BCR/ABL, and FIP1L1-PDGFRα.
  • Our results indicate that imatinib is of potential use in the treatment of mast cell sarcoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Mast-Cell Sarcoma / drug therapy. Mast-Cell Sarcoma / genetics. Piperazines / administration & dosage. Pyrimidines / administration & dosage. Uterine Neoplasms / drug therapy. Uterine Neoplasms / genetics

  • Genetics Home Reference. consumer health - FIP1L1 Gene.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • HSDB. structure - IMATINIB MESYLATE.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22020400.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / FIP1L1-PDGFRA fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 0 / mRNA Cleavage and Polyadenylation Factors; BKJ8M8G5HI / imatinib; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


12. |||||||||. 85%  Auquit-Auckbur I, Lazar C, Deneuve S, Guillemet C, Cordel N, Blanchard F, Joly P, Courville P: Malignant transformation of mastocytoma developed on skin mastocytosis into cutaneous mast cell sarcoma. Am J Surg Pathol; 2012 May;36(5):779-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of mastocytoma developed on skin mastocytosis into cutaneous mast cell sarcoma.
  • Mastocytosis is a group of disorders characterized by abnormal mast cell proliferation, involving the skin in 80% of cases.
  • Mast cell sarcomas, part of the systemic forms of mastocytosis, are very rare tumors characterized by a destructive growth of highly atypical mast cells, with secondary spread, poor prognosis, and low survival rates.
  • We report the first known case of primary cutaneous mast cell sarcoma due to the transformation of a benign solitary mastocytoma in an adult suffering from an unregressive localized cutaneous mastocytosis.
  • Histologic characteristics of the tumor, mutation analysis, and c-Kit expression were compared with available data.
  • Wide surgical excision of the tumor followed by adjuvant local radiotherapy were performed, and for the first time the use of imatinib was attempted, as neoplastic mast cells expressed the CD117 marker.
  • However, they failed to control the progression of sarcoma.
  • To date, no treatment is known to be effective for this disease, which is associated with short-term survival of the patients.
  • [MeSH-major] Cell Transformation, Neoplastic. Mast-Cell Sarcoma / pathology. Mastocytoma, Skin / pathology. Skin Neoplasms / pathology


13. ||||||||.. 75%  Bautista-Quach MA, Booth CL, Kheradpour A, Zuppan CW, Rowsell EH, Weiss L, Wang J: Mast cell sarcoma in an infant: a case report and review of the literature. J Pediatr Hematol Oncol; 2013 May;35(4):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell sarcoma in an infant: a case report and review of the literature.
  • Mast cell diseases comprise a spectrum of disorders including cutaneous mastocytosis, indolent or aggressive systemic variants including leukemia, and unifocal tumor formations such as benign extracutaneous mastocytoma or aggressive mast cell sarcoma (MCS).
  • Many mast cell diseases are associated with aberrancy of c-KIT proto-oncogene resulting in tyrosine kinase activity, typically exhibiting point mutation in codon 816.
  • MCS is an exceedingly rare clinicopathologic entity characterized by a unifocal accumulation of neoplastic mast cells that grow in a locally destructive manner.
  • We report a case in a 2-year-old boy who was initially diagnosed at 8 months of age with atypical cutaneous mastocytoma of the right ear with subsequent aggressive, destructive growth pattern; features that were most consistent with MCS.
  • So far, MCS has been documented in the literature in at least 6 human cases.
  • To the best of our knowledge, our case represents the first MCS in an infant.
  • [MeSH-major] Mast-Cell Sarcoma / diagnosis

  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23211696.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. |||||||... 73%  Kim YS, Wu H, Pawlowska AB, Bautista-Quach MA, Huang Q, Gaal K, Chang KL: Pediatric mast cell sarcoma of temporal bone with novel L799F (2395 C>T) KIT mutation, mimicking histiocytic neoplasm. Am J Surg Pathol; 2013 Mar;37(3):453-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric mast cell sarcoma of temporal bone with novel L799F (2395 C>T) KIT mutation, mimicking histiocytic neoplasm.
  • Mast cell sarcoma (MCS) is an extremely rare neoplasm with a clinically aggressive course.
  • Because of its rarity, its morphologic and molecular characteristics are still not well defined.
  • We report a case of a 15-year-old girl with MCS of the temporal bone extending into the posterior fossa creating a mass effect.
  • The KIT D816V mutation is frequently found in systemic mastocytosis, but it has not been documented in the few reported human MCS cases.
  • However, 1 reported case of MCS has shown a different alteration in the KIT gene.
  • Our case is the first MCS case with L799F mutation, located between the catalytic loop (790 to 797) and the activation loop (810 to 837) of the KIT gene, and only the second case of MCS with KIT mutation documented in the literature.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / genetics. Histiocytic Sarcoma / diagnosis. Mast-Cell Sarcoma / diagnosis. Mast-Cell Sarcoma / genetics. Mutation, Missense. Proto-Oncogene Proteins c-kit / genetics
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. DNA Mutational Analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Radiotherapy. Temporal Bone / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23388130.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


15. |||||..... 53%  Schwaab J, Horny HP, Jonescheit J, Metzgeroth G, Schafhausen P, Gaiser T, Marx A, Kienle P, Hofmann WK, Reiter A: Mast cell sarcoma mimicking metastatic colon carcinoma. Ann Hematol; 2014 Jun;93(6):1067-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell sarcoma mimicking metastatic colon carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colonic Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Mast-Cell Sarcoma / diagnosis. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Aged. Colon / chemistry. Colon / pathology. Eosinophils / pathology. Female. Gastrointestinal Hemorrhage / etiology. Humans. Hypereosinophilic Syndrome. Liver / chemistry. Liver / pathology. Mast Cells / pathology. Mastocytosis, Systemic. Neoplasms, Multiple Primary. Tumor Markers, Biological

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24141335.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tumor Markers, Biological
  •  go-up   go-down


16. ||||...... 40%  Georgin-Lavialle S, Aguilar C, Guieze R, Lhermitte L, Bruneau J, Fraitag S, Canioni D, Chandesris MO, Suarez F, Grandpeix-Guyodo C, Damaj G, Barete S, Aouba A, Fite C, Robert C, Gaulard P, Lortholary O, Tournilhac O, Dubreuil P, Hermine O: Mast cell sarcoma: a rare and aggressive entity--report of two cases and review of the literature. J Clin Oncol; 2013 Feb 20;31(6):e90-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell sarcoma: a rare and aggressive entity--report of two cases and review of the literature.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mast-Cell Sarcoma / diagnosis. Mast-Cell Sarcoma / drug therapy
  • [MeSH-minor] Adult. Antigens, CD30 / metabolism. Fatal Outcome. Genotype. Humans. Immunohistochemistry. Interleukin-2 Receptor alpha Subunit / metabolism. Male. Mast Cells / drug effects. Mast Cells / metabolism. Mast Cells / pathology. Proto-Oncogene Proteins c-kit / genetics. Proto-Oncogene Proteins c-kit / metabolism

  • ResearchGate. author profiles.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for mast-cell sarcoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23129735.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Interleukin-2 Receptor alpha Subunit; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


17. ||||...... 39%  Bugalia A, Abraham A, Balasubramanian P, Srivastava A, Nair S: Mast cell sarcoma of the small intestine: a case report. J Clin Pathol; 2011 Nov;64(11):1035-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell sarcoma of the small intestine: a case report.
  • [MeSH-major] Bone Neoplasms / pathology. Laryngeal Neoplasms / ultrastructure. Mast-Cell Sarcoma / pathology. Mast-Cell Sarcoma / ultrastructure. Tibia

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Pathol. 2007 Apr;60(4):424-5 [17405977.001]
  • [CommentOn] J Clin Pathol. 1986 Jun;39(6):596-602 [3088063.001]
  • (PMID = 21778298.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. |......... 7%  Su XY, Xu X, Tang Y, Li GD: [Diagnosis of hematolymphoid malignancy by using effusion fluid cytology specimens: a study of 33 cases]. Zhonghua Bing Li Xue Za Zhi; 2009 Aug;38(8):542-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of hematolymphoid malignancy by using effusion fluid cytology specimens: a study of 33 cases].
  • OBJECTIVE: To study the diagnostic accuracy of hematolymphoid malignancy by using effusion fluid cytology specimens and to evaluate the values of immunocytochemistry for this assay.
  • METHODS: The cytospin preparations/smears and cell block sections of effusion cytology specimens from 33 cases of hematolymphoid malignancy were retrospectively reviewed.
  • In selected cases, in-situ hybridization for Epstein-Barr virus-encoded RNA and immunoglobulin and T-cell receptor gene rearrangement study were carried out as indicated.
  • RESULTS: There were 33 cases of hematolymphoid malignancy, including 12 cases of T-lymphoblastic leukemia/lymphoma, 16 cases of mature B cell neoplasm (including 9 cases of diffuse large B-cell lymphoma, 2 cases of Burkitt lymphoma, 2 cases of plasmacytoma/multiple myeloma, 2 cases of B-small lymphocytic leukemia/lymphoma and 1 case of mantle cell lymphoma), 3 cases of mature T or NK-cell neoplasm (including 1 case of extranodal nasal NK/T-cell lymphoma, 1 case of angioimmunoblastic T-cell lymphoma and 1 case of T-cell prolymphocytic leukemia), 1 case of myeloid sarcoma and 1 case of mast cell sarcoma.
  • Amongst the 33 cases studied, 16 represented disease relapses, including 8 cases of diffuse large B-cell lymphoma, 2 cases of plasmacytoma/multiple myeloma, 2 cases of B-small lymphocytic leukemia/lymphoma, 1 case of T-lymphoblastic leukemia/lymphoma, 1 case of angioimmunoblastic T-cell lymphoma, 1 case of mantle cell lymphoma and 1 case of mast cell sarcoma.
  • The remaining 17 cases showed serous effusion as the primary manifestation, with the diagnosis primarily made upon cytologic examination.
  • The cytologic findings seen in all the 33 cases studied were in agreement with the corresponding histologic diagnosis.
  • CONCLUSIONS: Diagnosis of hematolymphoid malignancy by effusion fluid cytology specimens is possible, especially when coupled with the clinical history, immunophenotype, in-situ hybridization and gene rearrangement study findings.
  • This is especially so for cases with disease relapses.
  • [MeSH-major] Ascitic Fluid / pathology. Cytodiagnosis / methods. Lymphoma, Large B-Cell, Diffuse / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Child. Female. Humans. Immunohistochemistry. Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / metabolism. Lymphoma, Extranodal NK-T-Cell / pathology. Male. Middle Aged. Multiple Myeloma / diagnosis. Multiple Myeloma / metabolism. Multiple Myeloma / pathology. Plasmacytoma / diagnosis. Plasmacytoma / metabolism. Plasmacytoma / pathology. Retrospective Studies. Young Adult

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021966.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. |......... 5%  Ozdemir D, Dagdelen S, Erbas T: Systemic mastocytosis. Am J Med Sci; 2011 Nov;342(5):409-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Systemic mastocytosis (SM) is a clonal disorder of hematopoietic system characterized by abnormal growth and accumulation of mast cells in various tissues.
  • Its clinical spectrum ranges from mild disease to an aggressive course with life-threatening conditions.
  • Some of the clinical signs or symptoms of SM (hyperhidrosis, syncope and hypotensive/tachycardiac attacks) require consideration of pheochromocytoma and carcinoid syndrome in the differential diagnosis.
  • The diagnosis relies on the demonstration of mast cell aggregates in bone marrow or extracutaneous tissues.
  • The World Health Organization categorizes SM into 6 variants: indolent SM, SM with associated clonal hematological nonmast cell lineage disease, aggressive SM, mast cell leukemia, mast cell sarcoma and extracutaneous mastocytosis.
  • [MeSH-major] Mastocytosis, Systemic / diagnosis. Mastocytosis, Systemic / pathology. Mastocytosis, Systemic / physiopathology
  • [MeSH-minor] Cell Lineage. Humans. Mast Cells / pathology. Mast Cells / physiology. Proto-Oncogene Proteins c-kit / genetics. Tryptases / blood. World Health Organization

  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Systemic mastocytosis.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21629042.001).
  • [ISSN] 1538-2990
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


20. |......... 5%  Andersen CL, Kristensen TK, Severinsen MT, Møller MB, Vestergaard H, Bergmann OJ, Hasselbalch HC, Bjerrum OW: Systemic mastocytosis--a systematic review. Dan Med J; 2012 Mar;59(3):A4397
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The mast cell lives a hidden life, but it is implicated in several physiological reactions.
  • It is not until recent decades that the evolution of the cell has been described and its fascinating biology has only recently been depicted.
  • We here give a review of systemic mastocytosis in regards to cell biology, diagnostic approaches and clinical practice.
  • METHODS: A search was made in PubMed in August 2011 entering the keywords: mastocytosis, (systemic, cutaneous, aggressive), mast cell leukaemia, mast cell sarcoma, chromosome, mutation, haematology and treatment.
  • RESULTS: Mastocytosis is characterized by an abnormal proliferation of mast cells, which accumulate in one or several organ systems, primarily the skin and bone marrow.
  • The disease is clinically heterogeneous and varies from a relatively benign condition with isolated cutaneous lesions to a very aggressive systemic condition with a grave prognosis.
  • CONCLUSION: Patients with mastocytosis represent a heterogeneous group in terms of clinical presentation, management and prognosis.
  • [MeSH-major] Mast Cells / pathology. Mastocytosis, Systemic / pathology

  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Systemic mastocytosis.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22381091.001).
  • [ISSN] 2245-1919
  • [Journal-full-title] Danish medical journal
  • [ISO-abbreviation] Dan Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Histamine Antagonists
  •  go-up   go-down


21. |......... 3%  Cooper IF, Siadaty MS: 'Quantitative Concepts' associated with 'Cell Sarcoma Small': Top Publications. BioMedLib Review; QuantitativeConcept;CellSarcomaSmall:706354080. ISSN: 2331-5717. 2014/7/26
PDF icon [Fulltext service] Download fulltext PDF of this article.

  • [Title] 'Quantitative Concepts' associated with 'Cell Sarcoma Small': Top Publications.
  • There are articles published each month which present 'Quantitative Concept' for 'cell sarcoma small'.
  • Cooper IF et al: 'Steroids' associated with 'Cell Sarcoma Small': Top Publications.
  • Zhu H et al: Radiation-induced sarcoma in bronchial stump after thoracic radiation therapy for small-cell lung cancer.
  • Nakayama S et al: A rare case of primary clear cell sarcoma of the pubic bone resembling small round cell tumor: an unusual morphological variant.
  • Mahamid A et al: Small intestine perforation due to metastatic uterine cervix interdigitating dendritic cell sarcoma: a rare manifestation of a rare disease.
  • Shao H et al: Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases.
  • Subbiah V et al: Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1).
  • Lee AF et al: FLI-1 distinguishes Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma.
  • Bugalia A et al: Mast cell sarcoma of the small intestine: a case report.
  • Wang E et al: Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a 'transdifferentiation' during the clonal evolution.
  • Machado I et al: Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2014 Siadaty and Cooper; licensee BioMedLib LLC.
  • (UID = 706354080.001).
  • [ISSN] 2331-5717
  • [Journal-full-title] BioMedLib Review
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] UNITED STATES
  •  go-up   go-down


22. |......... 3%  Cooper IF, Siadaty MS: 'Steroids' associated with 'Cell Sarcoma Small': Top Publications. BioMedLib Review; Steroid;CellSarcomaSmall:705678565. ISSN: 2331-5717. 2014/6/26
PDF icon [Fulltext service] Download fulltext PDF of this article.

  • [Title] 'Steroids' associated with 'Cell Sarcoma Small': Top Publications.
  • There are articles published each month which present 'Steroid' for 'cell sarcoma small'.
  • Müller S et al: Type II collagen as specific marker for mesenchymal chondrosarcomas compared to other small cell sarcomas of the skeleton.
  • Fraser CR et al: Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone.
  • Nakayama S et al: A rare case of primary clear cell sarcoma of the pubic bone resembling small round cell tumor: an unusual morphological variant.
  • Terazawa K et al: Clear-cell sarcoma of the small intestine detected by FDG-PET/CT during comprehensive examination of an inflammatory reaction.
  • Subbiah V et al: Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1).
  • Ito E et al: A tetraspanin-family protein, T-cell acute lymphoblastic leukemia-associated antigen 1, is induced by the Ewing's sarcoma-Wilms' tumor 1 fusion protein of desmoplastic small round-cell tumor.
  • Glaser J et al: [Small-cell sarcoma of the esophagus as a fourth malignancy. Its palliative therapy with argon gas coagulation].
  • Venkataraman G et al: Clear cell sarcoma of the small bowel: a potential pitfall. Case report.
  • Bugalia A et al: Mast cell sarcoma of the small intestine: a case report.
  • Park SH et al: Small cell osteogenic sarcoma of the ribs: cytological, immunohistochemical, and ultrastructural study with literature review.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2014 Siadaty and Cooper; licensee BioMedLib LLC.
  • (UID = 705678565.001).
  • [ISSN] 2331-5717
  • [Journal-full-title] BioMedLib Review
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] UNITED STATES
  •  go-up   go-down


23. |......... 2%  Cooper IF, Siadaty MS: 'Cells' associated with 'Clinical Management': Top Publications. BioMedLib Review; Cell;ClinicalManagement:705803291. ISSN: 2331-5717. 2014/1/20
PDF icon [Fulltext service] Download fulltext PDF of this article.

  • [Title] 'Cells' associated with 'Clinical Management': Top Publications.
  • There are articles published each month which present 'Cell' for 'clinical management'.
  • Thakuria M et al: Update on the biology and clinical management of Merkel cell carcinoma.
  • Peveling-Oberhag J et al: Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management.
  • Goyal L: Clinical effectiveness of combining platelet rich fibrin with alloplastic bone substitute for the management of combined endodontic periodontal lesion.
  • Dourmishev LA et al: Clinical variants, stages, and management of basal cell carcinoma.
  • Zhu Y et al: Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients.
  • Krzemieniecki K et al: Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice.
  • Ribeiro IP et al: Genetic gains and losses in oral squamous cell carcinoma: impact on clinical management.
  • Weiler CR et al: Mast cell sarcoma: clinical management.
  • Shuch B et al: Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management.
  • Agochukwu N et al: Clinical management of renal cell carcinoma with venous tumor thrombus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2014 Siadaty and Cooper; licensee BioMedLib LLC.
  • (UID = 705803291.001).
  • [ISSN] 2331-5717
  • [Journal-full-title] BioMedLib Review
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] UNITED STATES
  •  go-up   go-down


24. |......... 2%  Cooper IF, Siadaty MS: 'Hormones' associated with 'Cell Sarcoma Small': Top Publications. BioMedLib Review; Hormone;CellSarcomaSmall:705150799. ISSN: 2331-5717. 2014/11/25
PDF icon [Fulltext service] Download fulltext PDF of this article.

  • [Title] 'Hormones' associated with 'Cell Sarcoma Small': Top Publications.
  • There are articles published each month which present 'Hormone' for 'cell sarcoma small'.
  • Müller S et al: Type II collagen as specific marker for mesenchymal chondrosarcomas compared to other small cell sarcomas of the skeleton.
  • Fraser CR et al: Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone.
  • Nakayama S et al: A rare case of primary clear cell sarcoma of the pubic bone resembling small round cell tumor: an unusual morphological variant.
  • Terazawa K et al: Clear-cell sarcoma of the small intestine detected by FDG-PET/CT during comprehensive examination of an inflammatory reaction.
  • Subbiah V et al: Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1).
  • Ito E et al: A tetraspanin-family protein, T-cell acute lymphoblastic leukemia-associated antigen 1, is induced by the Ewing's sarcoma-Wilms' tumor 1 fusion protein of desmoplastic small round-cell tumor.
  • Glaser J et al: [Small-cell sarcoma of the esophagus as a fourth malignancy. Its palliative therapy with argon gas coagulation].
  • Venkataraman G et al: Clear cell sarcoma of the small bowel: a potential pitfall. Case report.
  • Bugalia A et al: Mast cell sarcoma of the small intestine: a case report.
  • Choi EY et al: Undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: a novel highly aggressive soft tissue tumor with distinctive histopathology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2014 Siadaty and Cooper; licensee BioMedLib LLC.
  • (UID = 705150799.001).
  • [ISSN] 2331-5717
  • [Journal-full-title] BioMedLib Review
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] UNITED STATES
  •  go-up   go-down


25. |......... 2%  Hume CT, Kiupel M, Rigatti L, Shofer FS, Skorupski KA, Sorenmo KU: Outcomes of dogs with grade 3 mast cell tumors: 43 cases (1997-2007). J Am Anim Hosp Assoc; 2011 Jan-Feb;47(1):37-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of dogs with grade 3 mast cell tumors: 43 cases (1997-2007).
  • This study reports the outcomes of dogs with grade 3 mast cell tumors (MCTs).
  • Clinical and histopathological data were available for 43 dogs.
  • Tumor size, lymph node (LN) status, and mitotic index (MI) significantly influenced PFS in univariate analysis.
  • Tumor size and LN status remained significant in the multivariate analysis.
  • Lymph node status, local tumor control, LN treatment, and MI significantly influenced OS in univariate analysis but only LN status remained significant in multivariate analysis.
  • These results confirm that locoregional control improves outcomes in patients with grade 3 MCTs.
  • [MeSH-major] Dog Diseases / mortality. Mast-Cell Sarcoma / veterinary
  • [MeSH-minor] Animals. Disease-Free Survival. Dogs. Female. Immunohistochemistry / veterinary. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Mitotic Index. Multivariate Analysis. Neoplasm Staging / veterinary. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21164163.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. |......... 2%  Hahn KA, Legendre AM, Shaw NG, Phillips B, Ogilvie GK, Prescott DM, Atwater SW, Carreras JK, Lana SE, Ladue T, Rusk A, Kinet JP, Dubreuil P, Moussy A, Hermine O: Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. Am J Vet Res; 2010 Nov;71(11):1354-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
  • OBJECTIVE: To evaluate the effectiveness of masitinib for the treatment of nonresectable mast cell tumors (MCTs) in dogs at 12 and 24 months after onset of treatment.
  • After 6 months, treatment was extended with tumor assessments at 3-month intervals until detection of disease progression.
  • Endpoints were tumor response and overall survival rate and time.
  • Tumor control at 6 months had a high predictive value for 24-month survival, with high specificity (88%) and sensitivity (76%), whereas short-term tumor response (within 6 weeks) had a poor predictive value.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Masitinib significantly increased survival rates at 12 and 24 months in dogs with nonresectable MCTs.
  • Control of disease at 6 months, but not best response at 6 weeks, was predictive of long-term survival in dogs treated with masitinib, which suggested that short-term response may be irrelevant for assessing clinical efficacy of tyrosine kinase inhibitors for treatment of MCTs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Mast-Cell Sarcoma / veterinary

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Vet Res. 2011 Feb;72(2):247
  • (PMID = 21034327.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Thiazoles; M59NC4E26P / masitinib
  •  go-up   go-down


27. |......... 2%  Book AP, Fidel J, Wills T, Bryan J, Sellon R, Mattoon J: Correlation of ultrasound findings, liver and spleen cytology, and prognosis in the clinical staging of high metastatic risk canine mast cell tumors. Vet Radiol Ultrasound; 2011 Sep-Oct;52(5):548-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of ultrasound findings, liver and spleen cytology, and prognosis in the clinical staging of high metastatic risk canine mast cell tumors.
  • Cytologic sampling of the ultrasonographically normal spleen and liver is not implemented routinely in the clinical staging of canine cutaneous mast cell tumors and normal ultrasound findings are often accepted as sufficient evidence for ruling out splenic or liver metastasis.
  • Our objective was to define the specificity and sensitivity of ultrasound findings for diagnosis of mast cell infiltration when verified with cytologic evaluation, and to define the prognostic role of cytologic evaluation of liver and splenic aspirates.
  • Dogs with a diagnosis of clinically aggressive grade II, or grade III mast cell tumor treated with a combination vinblastine/CCNU chemotherapy protocol, were selected retrospectively based on availability of cytologic evaluation of spleen plus or minus liver for staging.
  • Out of 19 dogs, 10 dogs had a grade II tumor and nine a grade III tumor.
  • Seven dogs had mast cell infiltration of the spleen, liver, or both.
  • The sensitivity of ultrasound for detecting mast cell infiltration was 43% for the spleen and 0% for the liver.
  • Dogs with positive cytologic evidence of mast cell infiltration to spleen, liver, or both had significantly shorter survival (100 vs. 291 days) than dogs without evidence of mast cell infiltration (P<0.0001).
  • Routine splenic aspiration should be performed regardless of ultrasonographic appearance in dogs with a clinically aggressive mast cell tumor.
  • [MeSH-major] Dog Diseases / ultrasonography. Mast-Cell Sarcoma / secondary. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2011 Veterinary Radiology & Ultrasound.
  • (PMID = 21689203.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. |......... 2%  Stefanello D, Valenti P, Faverzani S, Bronzo V, Fiorbianco V, Pinto da Cunha N, Romussi S, Cantatore M, Caniatti M: Ultrasound-guided cytology of spleen and liver: a prognostic tool in canine cutaneous mast cell tumor. J Vet Intern Med; 2009 Sep-Oct;23(5):1051-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound-guided cytology of spleen and liver: a prognostic tool in canine cutaneous mast cell tumor.
  • BACKGROUND: In the clinical staging of cutaneous mast cell tumors (cMCT), the diagnosis of metastasis is controversial based on cytological examination of lymph nodes, spleen, liver, bone marrow, and blood.
  • ANIMALS: Fifty-two client-owned dogs with a diagnosis of cMCT.
  • RESULTS: Ten dogs with cMCT had mast cell infiltration of spleen, liver, or both and 4 of these dogs had involvement of the regional lymph nodes.
  • Dogs with positive evidence of mast cell infiltration to spleen, liver, or both had shorter survival times (34 versus 733 days) compared with dogs negative for mast cell infiltration at distant sites.
  • CONCLUSION AND CLINICAL IMPORTANCE: Dogs with evidence of mast cell infiltration at distant sites have a shorter survival times than dogs without evidence of infiltration at distant sites.
  • [MeSH-major] Dog Diseases / ultrasonography. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19656285.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine / American College of Veterinary Internal Medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. |......... 2%  Nagamine MK, Sanches DS, Pinello KC, Torres LN, Mennecier G, Latorre AO, Fukumasu H, Dagli ML: In vitro inhibitory effect of trichostatin A on canine grade 3 mast cell tumor. Vet Res Commun; 2011 Aug;35(6):391-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro inhibitory effect of trichostatin A on canine grade 3 mast cell tumor.
  • Mast cell tumor (MCT) is one of the most prevalent neoplasms that affect skin and soft tissue in dogs.
  • Because mast cell tumors present a great variety of clinical appearance and behavior, their treatment becomes a challenge.
  • MTT assay and trypan blue exclusion assays were performed to estimate cell growth and cell viability, and cell cycle analysis was evaluated.
  • TSA treatment showed a reduction in numbers of viable cells and an increase of cell death by apoptosis.
  • The cell cycle analysis showed an increase of hypodiploid cells and a reduction of G0/G1 and G2/M -phases.
  • [MeSH-major] Histone Deacetylase Inhibitors / pharmacology. Hydroxamic Acids / pharmacology. Mast-Cell Sarcoma / veterinary
  • [MeSH-minor] Acetylation. Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Dogs. Female. Histones / metabolism. Mice. Mice, Nude. Tetrazolium Salts / chemistry. Thiazoles / chemistry. Trypan Blue / chemistry

  • HSDB. structure - METHYLTHIAZOLETETRAZOLIUM.
  • HSDB. structure - TRYPAN BLUE.
  • ResearchGate. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21472452.001).
  • [ISSN] 1573-7446
  • [Journal-full-title] Veterinary research communications
  • [ISO-abbreviation] Vet. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; 0 / Histones; 0 / Hydroxamic Acids; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; 3X2S926L3Z / trichostatin A; I2ZWO3LS3M / Trypan Blue
  •  go-up   go-down


30. |......... 1%  Taylor F, Gear R, Hoather T, Dobson J: Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases. J Small Anim Pract; 2009 Jun;50(6):284-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases.
  • OBJECTIVES: To evaluate the response of measurable canine mast cell tumours unsuitable for other treatment modalities to a chemotherapy protocol comprising chlorambucil and prednisolone.
  • METHODS: Dogs bearing measurable mast cell tumours, unsuitable for treatment by surgery or radiotherapy, were treated with orally administered prednisolone and chlorambucil, and their responses assessed.
  • RESULTS: Twenty-one dogs were enrolled in the study; 13 had intermediate-grade mast cell tumour, six were high grade and two were diagnosed by cytology alone.
  • Eight dogs had multiple tumours and 13 dogs had single tumours, and six dogs had lymph node metastases and no dogs had visceral metastases detected.
  • Three dogs achieved complete remission, five achieved partial remission (overall response rate 38 per cent), nine had static disease and four dogs had progressive disease.
  • Progression-free interval and median survival time were not influenced by the age, sex, weight or neutering status of the patient, by the grade or stage of the tumour or whether the patient had single or multiple tumours.
  • CLINICAL SIGNIFICANCE: Response and survival rates of inoperable canine MCT to chlorambucil and prednisolone are comparable to previously described protocols, with no apparent toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dog Diseases / drug therapy. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Chlorambucil / therapeutic use. Disease Progression. Dogs. Female. Lymphatic Metastasis. Male. Neoplasm Staging / veterinary. Prednisolone / therapeutic use. Prospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • HSDB. structure - CHLORAMBUCIL.
  • HSDB. structure - PREDNISOLONE.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19527421.001).
  • [ISSN] 1748-5827
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 18D0SL7309 / Chlorambucil; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


31. |......... 1%  Pokorny E, Hecht S, Sura PA, LeBlanc AK, Phillips J, Conklin GA, Haifley KA, Newkirk K: Magnetic resonance imaging of canine mast cell tumors. Vet Radiol Ultrasound; 2012 Mar-Apr;53(2):167-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of canine mast cell tumors.
  • Mast cell tumors (MCT) are the most common cutaneous tumors in dogs.
  • The signal intensity of tumors and lymph nodes was compared to adjacent musculature.
  • All tumors were strongly contrast enhancing; 5/9 were homogeneous and 4/9 heterogeneous in their enhancement patterns.
  • MR imaging may be useful in the presurgical evaluation and clinical staging of cutaneous MCT.
  • [MeSH-major] Dog Diseases / diagnosis. Magnetic Resonance Imaging / veterinary. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22136427.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. |......... 1%  Henry C, Herrera C: Mast cell tumors in cats: clinical update and possible new treatment avenues. J Feline Med Surg; 2013 Jan;15(1):41-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cell tumors in cats: clinical update and possible new treatment avenues.
  • PRACTICAL RELEVANCE: Feline mast cell tumors (MCTs) are frequently encountered in general practice.
  • MCTs are the most common splenic tumor, second most common skin tumor and third most common intestinal tumor in cats.
  • CLINICAL CHALLENGES: While a cytologic or histologic diagnosis is often easy to obtain, the various histologic classifications, lack of a relevant grading scheme, and disparity in behavior depending on anatomic location make prognostication for cases of feline MCTs confusing.
  • This is quite different from canine MCTs, where there is an established grading system which correlates clinically with prognosis and an accepted standard of care.
  • In many instances, referral for diagnosis and treatment is not necessary.
  • EVIDENCE BASE: Historically, there has been limited clinical evidence upon which to determine optimal treatment of MCTs in cats.
  • [MeSH-major] Cat Diseases / diagnosis. Cat Diseases / therapy. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23254240.001).
  • [ISSN] 1532-2750
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


33. |......... 1%  Taney K, Smith MM: Resection of mast cell tumor of the lip in a dog. J Vet Dent; 2009;26(1):28-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of mast cell tumor of the lip in a dog.
  • A 10-year-old Boston terrier dog was presented for treatment of a 2-cm mast cell tumor of the left upper lip and nasal planum immediately adjacent to the philtrum and ventral to the nares.
  • [MeSH-major] Dog Diseases / surgery. Lip Neoplasms / veterinary. Mast-Cell Sarcoma / veterinary

  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Vet Dent. 2009 Summer;26(2):120
  • (PMID = 19476085.001).
  • [ISSN] 0898-7564
  • [Journal-full-title] Journal of veterinary dentistry
  • [ISO-abbreviation] J Vet Dent
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. |......... 1%  Spugnini EP, Vincenzi B, Citro G, Dotsinsky I, Mudrov T, Baldi A: Evaluation of Cisplatin as an electrochemotherapy agent for the treatment of incompletely excised mast cell tumors in dogs. J Vet Intern Med; 2011 Mar-Apr;25(2):407-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of Cisplatin as an electrochemotherapy agent for the treatment of incompletely excised mast cell tumors in dogs.
  • BACKGROUND: Electrochemotherapy (ECT) couples the administration of anticancer drugs with the delivery of electric pulses that increase the drug uptake through the cell membranes, resulting in an improved efficacy.
  • HYPOTHESIS: To evaluate the tolerability and efficacy of cisplatin (CDDP) as an ECT agent to prevent recurrence of incompletely resected mast cell tumors (MCTs).
  • After debulking, the tumor bed and margins were infiltrated with CDDP, and then exposed to trains of biphasic electrical pulses under sedation.
  • A second session was performed 1 or 2 weeks later based on clinical considerations.
  • Twenty-nine dogs had no evidence of recurrence over the 6-year study period, 6 had tumor recurrence, 1 died of multiple cutaneous MCTs, and 1 died of unrelated causes.
  • CONCLUSIONS AND CLINICAL IMPORTANCE: ECT with CDDP appears effective in the treatment of incompletely resected MCT in dogs and could be a useful addition to the current options based on its low cost, limited toxicity, and ease of administration.
  • [MeSH-major] Dog Diseases / drug therapy. Electrochemotherapy / veterinary. Mast-Cell Sarcoma / veterinary

  • HSDB. structure - CIS-DIAMINEDICHLOROPLATINUM.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 by the American College of Veterinary Internal Medicine.
  • (PMID = 21382075.001).
  • [ISSN] 1939-1676
  • [Journal-full-title] Journal of veterinary internal medicine / American College of Veterinary Internal Medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


35. |......... 1%  Schultheiss PC, Gardiner DW, Rao S, Olea-Popelka F, Tuohy JL: Association of histologic tumor characteristics and size of surgical margins with clinical outcome after surgical removal of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc; 2011 Jun 1;238(11):1464-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of histologic tumor characteristics and size of surgical margins with clinical outcome after surgical removal of cutaneous mast cell tumors in dogs.
  • OBJECTIVE: To evaluate the relationship between width and depth of surgical margins, amount of edema within and around the tumor, and degree of demarcation between the tumor and surrounding tissues with the clinical outcome following surgical removal of cutaneous mast cell tumors (cMCTs) in dogs.
  • PROCEDURES: Information about the dogs' clinical outcomes following cMCT removal was obtained from primary care veterinarians.
  • Histologic sections of excised tumors were assessed retrospectively for tumor grade and measurement of the narrowest lateral and deep margins of nonneoplastic tissue excised with the tumors; edema within the tumor and surrounding tissues was assessed as minimal, moderate, or severe.
  • Tumors were classified as poorly, moderately, or well demarcated on the basis of the degree of mast cell infiltration into the adjoining connective tissue.
  • RESULTS: Following tumor excision (with no additional postsurgery treatment), 96 dogs had no local recurrence or metastatic disease for 27 to 31 months; 4 metastatic disease-related deaths (dogs with grade II or III tumors) occurred within 3 to 9 months.
  • Histologically, mean lateral and deep surgical margins around the tumors were 8.9 and 5.3 mm, respectively.
  • No recurrence of tumor or metastatic disease developed following excision with lateral margins ≥ 10 mm and deep margins ≥ 4 mm.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that most grade I and II cMCTs in dogs can be successfully treated by complete surgical removal with margins smaller than those currently recommended.
  • [MeSH-major] Dog Diseases / pathology. Dog Diseases / surgery. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Vet Med Assoc. 2011 Aug 1;239(3):297; author reply 297 [21801039.001]
  • (PMID = 21627510.001).
  • [ISSN] 1943-569X
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. |......... 1%  Cooper MA, Bennett PF, Laverty PH: Metastatic mast cell tumour in a dog presenting with spinal pain. Aust Vet J; 2009 Apr;87(4):157-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic mast cell tumour in a dog presenting with spinal pain.
  • The clinical, advanced imaging and surgical features of a case of canine extradural mast cell tumour are presented.
  • Given the frequent occurrence and treatment of cutaneous mast cell tumours in dogs, the finding of spinal metastasis is an important reminder to consider metastatic neoplasia in cases of previously treated cancers presenting with spinal pain.
  • [MeSH-major] Dog Diseases / diagnosis. Dog Diseases / pathology. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary. Spinal Neoplasms / veterinary
  • [MeSH-minor] Animals. Antineoplastic Agents / administration & dosage. Dogs. Euthanasia, Animal. Male. Myelography / veterinary. Pain / diagnosis. Pain / veterinary. Spinal Cord / pathology. Spinal Cord / radiography

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19335472.001).
  • [ISSN] 0005-0423
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


37. |......... 1%  Krick EL, Billings AP, Shofer FS, Watanabe S, Sorenmo KU: Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival. Vet Comp Oncol; 2009 Jun;7(2):130-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival.
  • The purpose of this retrospective cohort study is to describe the association of cytological assessment of lymph node metastasis with survival and tumour grade in dogs with mast cell tumours.
  • Regional lymph node aspirates of 152 dogs diagnosed with a mast cell tumour were reviewed and classified according to specific cytological criteria for staging.
  • 97 dogs (63.8%) had stage I tumours, and 55 (36.2%) had stage II tumours.
  • Stage II dogs had a significantly shorter survival time than dogs with stage I disease (0.8 and 6.2 years, respectively; P < 0.0001).
  • Dogs with grade III mast cell tumours were more likely to have stage II disease (P = 0.004).
  • These results suggest that cytological evaluation of lymph nodes in dogs with mast cell tumours provides useful and valuable clinical information, and the results correlate with tumour grade and outcome thus providing a practical and non-invasive method for staging.
  • [MeSH-major] Dog Diseases / mortality. Dog Diseases / pathology. Lymph Nodes / cytology. Mast-Cell Sarcoma / veterinary. Neoplasm Staging / veterinary

  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19453367.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. |......... 1%  Moiseeva EP, Leyland ML, Bradding P: CADM1 isoforms differentially regulate human mast cell survival and homotypic adhesion. Cell Mol Life Sci; 2012 Aug;69(16):2751-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CADM1 isoforms differentially regulate human mast cell survival and homotypic adhesion.
  • Cell adhesion molecule 1 (CADM1), expressed by human lung mast cells (HLMCs), mediates their adhesion to airway smooth muscle (ASM), and contributes to ASM-dependent HLMC proliferation and survival.
  • In contrast, CADM1 downregulation abolished homotypic adhesion, indicating that CADM1 is the sole receptor mediating mast cell aggregation.
  • CADM1-mediated adhesion was enhanced by the presence of cell survival factors.
  • SP1 overexpression in HMC-1 cells compromised survival compared to SP4 overexpression or control.
  • In summary, human MCs express multiple CADM1 isoforms which exhibit differential regulation of survival and homotypic adhesion.
  • [MeSH-major] Cell Adhesion. Cell Adhesion Molecules / metabolism. Immunoglobulins / metabolism. Leukemia, Mast-Cell / pathology. Lung / cytology. Mast Cells / cytology. Mast-Cell Sarcoma / pathology
  • [MeSH-minor] Blotting, Western. Cell Aggregation. Cell Survival. Cells, Cultured. Humans. Protein Isoforms. RNA, Messenger / genetics. Real-Time Polymerase Chain Reaction. Reverse Transcriptase Polymerase Chain Reaction

  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2008 Apr 15;180(8):5466-76 [18390729.001]
  • [Cites] Oncogene. 2008 May 22;27(23):3329-38 [18084322.001]
  • [Cites] Nat Protoc. 2008;3(6):1101-8 [18546601.001]
  • [Cites] J Immunol. 2008 Aug 15;181(4):2772-80 [18684968.001]
  • [Cites] Neurosci Lett. 2008 Oct 17;444(1):16-21 [18718504.001]
  • [Cites] J Virol. 2008 Dec;82(23):11958-63 [18922876.001]
  • [Cites] Biochem Pharmacol. 2008 Dec 1;76(11):1352-64 [18708031.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Dec 19;377(3):926-9 [18957284.001]
  • [Cites] Nat Biotechnol. 2009 Apr;27(4):378-86 [19349973.001]
  • [Cites] Am J Clin Pathol. 2009 Sep;132(3):438-47 [19687320.001]
  • [Cites] J Biol Chem. 2009 Aug 28;284(35):23793-805 [19561085.001]
  • [Cites] FEBS Lett. 2009 Sep 3;583(17):2758-64 [19683529.001]
  • [Cites] Blood. 2009 Oct 1;114(14):3084-91 [19643986.001]
  • [Cites] Blood. 2009 Dec 17;114(26):5342-51 [19850739.001]
  • [Cites] J Biol Chem. 2010 May 14;285(20):15511-22 [20215110.001]
  • [Cites] FEBS Lett. 2010 Jul 16;584(14):2981-9 [20540941.001]
  • [Cites] Eur J Immunol. 2010 Jul;40(7):1843-51 [20583030.001]
  • [Cites] Nucleic Acids Res. 2011 Jan;39(Database issue):D800-6 [21045057.001]
  • [Cites] Nucleic Acids Res. 2011 Jan;39(Database issue):D38-51 [21097890.001]
  • [Cites] Nat Rev Mol Cell Biol. 2011 Mar;12(3):189-97 [21346732.001]
  • [Cites] Adv Exp Med Biol. 2011;716:235-69 [21713660.001]
  • [Cites] Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14210-5 [21825171.001]
  • [Cites] Glycobiology. 2012 Jan;22(1):12-22 [21725073.001]
  • [Cites] Blood. 2011 Dec 22;118(26):6930-8 [22001390.001]
  • [Cites] J Immunol. 2006 Jan 15;176(2):1238-43 [16394014.001]
  • [Cites] Nat Rev Immunol. 2007 Feb;7(2):93-104 [17259966.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3031-41 [17110460.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):4045-52 [17785843.001]
  • [Cites] J Neurosci. 2007 Nov 14;27(46):12516-30 [18003830.001]
  • [Cites] Mol Cancer Ther. 2007 Nov;6(11):3071-9 [18025290.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59 [18097445.001]
  • [Cites] Genomics. 1999 Dec 1;62(2):139-46 [10610705.001]
  • [Cites] J Leukoc Biol. 2000 Jul;68(1):38-46 [10914488.001]
  • [Cites] Lab Invest. 2000 Oct;80(10):1571-81 [11045574.001]
  • [Cites] Nat Genet. 2001 Apr;27(4):427-30 [11279526.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2601-8 [12456501.001]
  • [Cites] Leuk Res. 2003 Aug;27(8):671-6 [12801523.001]
  • [Cites] Leuk Res. 2003 Aug;27(8):677-82 [12801524.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1002-7 [12942568.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6320-6 [14559819.001]
  • [Cites] APMIS. 2003 Nov;111(11):1067-74 [14629273.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 18;319(1):200-6 [15158462.001]
  • [Cites] Oncogene. 2004 Jul 22;23(33):5687-92 [15184876.001]
  • [Cites] Cell Mol Life Sci. 2004 Sep;61(17):2189-99 [15338051.001]
  • [Cites] Leuk Res. 1988;12(4):345-55 [3131594.001]
  • [Cites] Blood. 1997 May 1;89(9):3296-302 [9129035.001]
  • [Cites] Scand J Immunol. 1997 May;45(5):471-81 [9160089.001]
  • [Cites] Glycobiology. 2005 Feb;15(2):153-64 [15385431.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1204-13 [15471956.001]
  • [Cites] Genomics. 2006 Jan;87(1):139-50 [16311015.001]
  • (PMID = 22438059.001).
  • [ISSN] 1420-9071
  • [Journal-full-title] Cellular and molecular life sciences : CMLS
  • [ISO-abbreviation] Cell. Mol. Life Sci.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / 87834; United Kingdom / Medical Research Council / / G0801164
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CADM1 protein, human; 0 / Cell Adhesion Molecules; 0 / Immunoglobulins; 0 / Protein Isoforms; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC3400039
  •  go-up   go-down


39. |......... 1%  Ziekman PG, Otter WD, Tan JF, Teske E, Kirpensteijn J, Koten JW, Jacobs JJ: Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs. Anticancer Res; 2013 Jan;33(1):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs.
  • AIM: Mast cell tumours (MCT) are common skin tumours in dogs.
  • If complete surgical removal of the tumours is not possible, then another therapy is needed.
  • The tumours were injected with 4.5×10(6) IU IL-2.
  • RESULTS: The early clinical effects in the seven dogs with cutaneous MCT were: complete regression (CR) in two dogs; partial regression (PR) in four, and stable disease (SD) in one dog.
  • The final clinical effects were CR in three dogs, PR in two dogs, and PD in two dogs.
  • [MeSH-major] Genetic Therapy. Interleukin-2 / therapeutic use. Mast-Cell Sarcoma / genetics. Mast-Cell Sarcoma / therapy

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23267141.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Interleukin-2
  •  go-up   go-down


40. |......... 1%  Hosoya K, Kisseberth WC, Alvarez FJ, Lara-Garcia A, Beamer G, Stromberg PC, Couto CG: Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors. J Am Anim Hosp Assoc; 2009 Jan-Feb;45(1):14-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors.
  • The use of adjuvant 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; lomustine) to treat incompletely excised canine mast cell tumors (MCTs) has not been evaluated.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Dog Diseases / drug therapy. Lomustine / therapeutic use. Mast-Cell Sarcoma / veterinary. Prednisone / therapeutic use

  • MedlinePlus Health Information. consumer health - Steroids.
  • HSDB. structure - LOMUSTINE.
  • HSDB. structure - PREDNISONE.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122059.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 7BRF0Z81KG / Lomustine; VB0R961HZT / Prednisone
  •  go-up   go-down


41. |......... 1%  Matsuda K, Sakaguchi K, Kobayashi S, Tominaga M, Hirayama K, Kadosawa T, Taniyama H: Systemic candidiasis and mesenteric mast cell tumor with multiple metastases in a dog. J Vet Med Sci; 2009 Feb;71(2):229-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic candidiasis and mesenteric mast cell tumor with multiple metastases in a dog.
  • A 5-year-old female miniature dachshund presenting with persistent vomiting and diarrhea had two concurrent rare pathological conditions: systemic candidiasis and mesenteric mast cell tumor with multiorgan metastases.
  • Neoplastic mast cells formed mass in the mesentery of the cecal-colonic region and were also found in the liver, spleen, kidneys, lungs, adrenal grands, ovaries, bone marrow and other tissues.
  • [MeSH-major] Candida albicans / growth & development. Candidiasis / veterinary. Dog Diseases / microbiology. Mast-Cell Sarcoma / veterinary. Mesentery / pathology

  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19262039.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science / the Japanese Society of Veterinary Science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


42. |......... 1%  Scarpa F, Sabattini S, Marconato L, Capitani O, Morini M, Bettini G: Use of histologic margin evaluation to predict recurrence of cutaneous malignant tumors in dogs and cats after surgical excision. J Am Vet Med Assoc; 2012 May 15;240(10):1181-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of histologic margin evaluation to predict recurrence of cutaneous malignant tumors in dogs and cats after surgical excision.
  • OBJECTIVE: To assess the usefulness of histologic evaluation of surgical margins to predict local recurrence of cutaneous malignant tumors in dogs and cats treated by means of surgical excision.
  • PROCEDURES: 60 surgically excised tumors (20 soft tissue sarcomas [STSs], 20 mast cell tumors [MCTs], and 20 carcinomas) were examined histologically.
  • RESULTS: Surgical margins were clean in 29 of 60 (48%) tumors, close in 11 (18%), and infiltrated in 20 (33%).
  • Tumors recurred in 27 of 60 (45%) animals, with a mean ± SD RFI of 229 ± 173 days.
  • Recurrence rates for animals that had tumors with infiltrated (16/20) or close (8/11) margins were significantly higher than recurrence rate for animals that had tumors with clean margins (3/29).
  • CONCLUSIONS AND CLINICAL RELEVANCE: Histologic assessment of margin status was useful for predicting local recurrence of cutaneous malignant tumors in dogs and cats treated by means of excision alone.
  • Method accuracy varied among tumor types and grades.
  • Results were similar for animals with infiltrated and close tumor margins, and careful postsurgical management is recommended for both.
  • [MeSH-minor] Animals. Carcinoma / mortality. Carcinoma / pathology. Carcinoma / surgery. Carcinoma / veterinary. Cats. Disease-Free Survival. Dogs. Female. Male. Mast-Cell Sarcoma / mortality. Mast-Cell Sarcoma / pathology. Mast-Cell Sarcoma / surgery. Mast-Cell Sarcoma / veterinary. Neoplasm Recurrence, Local / veterinary. Predictive Value of Tests. Prospective Studies. Sarcoma / mortality. Sarcoma / pathology. Sarcoma / surgery. Sarcoma / veterinary. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22559107.001).
  • [ISSN] 1943-569X
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. |......... 1%  Fröberg GK, Lindberg R, Ritter M, Nordlind K: Expression of serotonin and its 5-HT1A receptor in canine cutaneous mast cell tumours. J Comp Pathol; 2009 Aug-Oct;141(2-3):89-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of serotonin and its 5-HT1A receptor in canine cutaneous mast cell tumours.
  • Mast cells of a number of different animal species have been reported to contain serotonin (5-hydroxytryptamine; 5-HT), a monoamine capable of numerous and complex actions, which may include an impact on tumour growth.
  • Limited previous studies have suggested that normal or neoplastic canine mast cells do not express 5-HT.
  • In the present study, canine cutaneous mast cell tumours (MCTs) of Patnaik histological grades I-III were investigated immunohistochemically for expression of 5-HT and its receptor (R) 5-HT1A.
  • Both 5-HT and the 5-HT1A receptor were expressed by non-neoplastic dermal mast cells and neoplastic mast cells.
  • More neoplastic mast cells expressed 5-HT than the 5-HT1AR.
  • Poorly differentiated tumours expressed fewer of both molecules, but the better differentiated mast cells at the periphery of such lesions had more consistent 5-HT expression.
  • [MeSH-major] Dog Diseases / metabolism. Mast-Cell Sarcoma / veterinary. Receptor, Serotonin, 5-HT1A / metabolism. Serotonin / metabolism. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Dogs. Fluorescent Antibody Technique, Direct / methods. Fluorescent Antibody Technique, Direct / veterinary. Immunoenzyme Techniques / methods. Immunoenzyme Techniques / veterinary. Mast Cells / metabolism. Neoplasm Staging / veterinary. Skin / metabolism. Tumor Markers, Biological / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19446835.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Markers, Biological; 112692-38-3 / Receptor, Serotonin, 5-HT1A; 333DO1RDJY / Serotonin
  •  go-up   go-down


44. |......... 1%  Peter B, Cerny-Reiterer S, Hadzijusufovic E, Schuch K, Stefanzl G, Eisenwort G, Gleixner KV, Hoermann G, Mayerhofer M, Kundi M, Baumgartner S, Sperr WR, Pickl WF, Willmann M, Valent P: The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. J Leukoc Biol; 2014 Jan;95(1):95-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
  • In this study, we examined the effects of the pan-Bcl-2 family blocker obatoclax (GX015-070) on primary neoplastic MC, the human MC leukemia cell line HMC-1, and the canine mastocytoma cell line C2.
  • [MeSH-major] Apoptosis / drug effects. Apoptosis Regulatory Proteins / genetics. Gene Expression Regulation, Neoplastic / drug effects. Mast-Cell Sarcoma / genetics. Membrane Proteins / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Pyrroles / pharmacology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Cell Proliferation / drug effects. Drug Resistance, Neoplasm / genetics. Drug Synergism. Female. Humans. Male. Middle Aged. Myeloid Cell Leukemia Sequence 1 Protein / genetics. RNA, Messenger / genetics. bcl-X Protein / genetics

  • HSDB. structure - PYRROLE.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24052572.001).
  • [ISSN] 1938-3673
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / BBC3 protein, human; 0 / Bcl-2-like protein 11; 0 / MCL1 protein, human; 0 / Membrane Proteins; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / PMAIP1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrroles; 0 / RNA, Messenger; 0 / bcl-X Protein; 0 / obatoclax
  • [Keywords] NOTNLM ; Mcl-1 / mastocytosis / targeted therapy
  •  go-up   go-down


45. |......... 1%  London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM: Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res; 2009 Jun 1;15(11):3856-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
  • PURPOSE: The purpose of this study was to determine the objective response rate (ORR) following treatment of canine mast cell tumors (MCT) with toceranib phosphate (Palladia, SU11654), a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRbeta.
  • Secondary objectives were to determine biological response rate, time to tumor progression, duration of objective response, health-related quality of life, and safety of Palladia.
  • The ORR for all 145 dogs receiving Palladia was 42.8% (21 complete response, 41 partial response); among the 62 responders, the median duration of objective response and time to tumor progression was 12.0 weeks and 18.1 weeks, respectively.
  • This clinical trial further shows that spontaneous tumors in dogs are good models to evaluate therapeutic index of targeted therapeutics in a clinical setting.
  • [MeSH-major] Dog Diseases / drug therapy. Indoles / therapeutic use. Mast-Cell Sarcoma / drug therapy. Pyrroles / therapeutic use. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
  • [MeSH-minor] Animals. Anorexia / chemically induced. Diarrhea / chemically induced. Disease Progression. Dogs. Female. Male. Neoplasm Recurrence, Local. Random Allocation. Treatment Outcome. Vomiting / chemically induced

  • HSDB. structure - PYRROLE.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2009 Jun 1;15(11):3645-7 [19470723.001]
  • (PMID = 19470739.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / Pyrroles; 24F9PF7J3R / toceranib phosphate; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


46. |......... 1%  Sekis I, Gerner W, Willmann M, Rebuzzi L, Tichy A, Patzl M, Thalhammer JG, Saalmüller A, Kleiter MM: Effect of radiation on vascular endothelial growth factor expression in the C2 canine mastocytoma cell line. Am J Vet Res; 2009 Sep;70(9):1141-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of radiation on vascular endothelial growth factor expression in the C2 canine mastocytoma cell line.
  • OBJECTIVE: To establish the radiosensitivity and effect of irradiation on vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) expression in the canine mastocytoma cell line C2.
  • SAMPLE POPULATION: Canine mastocytoma cell line C2.
  • The 3-(4, 5-di-methyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide assay and proliferation assays with (methyl-hydrogen 3) thymidine were used for radiosensitivity experiments.
  • Cell survival rates decreased in a dose-dependent manner.
  • The apoptotic cell fraction had a dose-dependent increase that reached its maximum 24 to 48 hours after radiation.
  • CONCLUSIONS AND CLINICAL RELEVANCE: The C2 cell line was radiosensitive, and a fraction (up to 40%) of cells died via apoptosis in a dose-dependent manner.
  • Further studies are needed to determine whether tumor control could be improved by combining radiotherapy with VEGFR inhibitors or apoptosis-modulating agents.
  • [MeSH-major] Dog Diseases / radiotherapy. Mast-Cell Sarcoma / veterinary. Vascular Endothelial Growth Factor A / genetics
  • [MeSH-minor] Animals. Annexin A5 / genetics. Apoptosis / radiation effects. Cell Division / radiation effects. Cell Line, Tumor. Dogs. Dose-Response Relationship, Radiation. Humans. Vascular Endothelial Growth Factor Receptor-1 / genetics

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19719431.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


47. |......... 1%  Knobloch A, Mohring SA, Eberle N, Nolte I, Hamscher G, Simon D: Drug residues in serum of dogs receiving anticancer chemotherapy. J Vet Intern Med; 2010 Mar-Apr;24(2):379-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ANIMALS: Twenty-seven client-owned dogs treated for lymphoma or mast cell tumors with vincristine, vinblastine, cyclophosphamide, or doxorubicin.
  • Serum samples were either taken 7 days after administration of vincristine, cyclophosphamide, doxorubicin (lymphoma), and vinblastine (mast cell tumor), or 1-2 days after the last concurrent oral administration of cyclophosphamide (mast cell tumor).
  • CONCLUSIONS AND CLINICAL IMPORTANCE: Handling of blood samples from dogs receiving oncolytic chemotherapy 7 days after treatment with vincristine, vinblastine, cyclophosphamide, and doxorubicin should not present a health hazard.
  • [MeSH-minor] Animals. Dogs. Lymphoma / drug therapy. Lymphoma / veterinary. Mast-Cell Sarcoma / drug therapy. Mast-Cell Sarcoma / veterinary. Prospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20102504.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine / American College of Veterinary Internal Medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


48. |......... 1%  Giantin M, Vascellari M, Lopparelli RM, Ariani P, Vercelli A, Morello EM, Cristofori P, Granato A, Buracco P, Mutinelli F, Dacasto M: Expression of the aryl hydrocarbon receptor pathway and cyclooxygenase-2 in dog tumors. Res Vet Sci; 2013 Feb;94(1):90-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the aryl hydrocarbon receptor pathway and cyclooxygenase-2 in dog tumors.
  • As the domestic dog represents a valuable animal model in comparative oncology, mRNA levels of cytochromes P450 1A1, 1A2 and 1B1 (CYP1A1, 1A2 and 1B1), AHR, AHR nuclear translocator (ARNT), AHR repressor (AHRR, whose partial sequence was here obtained) and cyclooxygenase-2 (COX2) were measured in dog control tissues (liver, skin, mammary gland and bone), in 47 mast cell tumors (MCTs), 32 mammary tumors (MTs), 5 osteosarcoma (OSA) and related surgical margins.
  • Furthermore, their pattern of expression in tumor biopsies was comparable to that already described in a variety of human cancers; in particular, both AHR and COX2 genes were up-regulated and positively correlated, while CYP1A1 and CYP1A2 mRNAs were generally poorly expressed.
  • [MeSH-minor] Animals. Breast Neoplasms / enzymology. Breast Neoplasms / metabolism. Breast Neoplasms / veterinary. Dogs. Female. Male. Mast-Cell Sarcoma / enzymology. Mast-Cell Sarcoma / metabolism. Mast-Cell Sarcoma / veterinary. Osteosarcoma / enzymology. Osteosarcoma / metabolism. Osteosarcoma / veterinary. Real-Time Polymerase Chain Reaction / veterinary

  • MedlinePlus Health Information. consumer health - Cancer.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2012 Elsevier Ltd. All rights reserved.
  • (PMID = 22925934.001).
  • [ISSN] 1532-2661
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Aryl Hydrocarbon; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


49. |......... 1%  Schlieben P, Meyer A, Weise C, Bondzio A, Gruber AD, Klopfleisch R: Tandem duplication of KIT exon 11 influences the proteome of canine mast cell tumours. J Comp Pathol; 2013 May;148(4):318-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem duplication of KIT exon 11 influences the proteome of canine mast cell tumours.
  • Mutations with permanent activation of the stem cell factor receptor KIT have been identified as one potential cause for canine cutaneous mast cell tumours (MCTs).
  • The exact changes in global gene expression patterns associated with permanent activation of KIT in these tumours are unknown.
  • These are mainly involved in cytoskeleton structure and cell motility (ACTR2, ACTB and CAPPA1), cell signalling (ARHGDIA) and lipid metabolism (ALOX15 and ACSBG4), or are serum proteins.
  • The results therefore support the notion that KIT mutation is associated with changes in the proteome of affected cells with a major effect on the composition of the cytoskeletal proteome and cell motility proteins.
  • No overlaps were identified when the results were compared with a recent study on the proteomic differences between low- and high-grade tumours, suggesting that KIT-mutated tumours may be regarded as a separate entity of high-grade tumours with potential relevance to therapeutic strategies.
  • [MeSH-major] Mast Cells / metabolism. Mast-Cell Sarcoma / veterinary. Proto-Oncogene Proteins c-kit / genetics. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2012 Elsevier Ltd. All rights reserved.
  • (PMID = 22935087.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proteome; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


50. |......... 1%  White CR, Hohenhaus AE, Kelsey J, Procter-Gray E: Cutaneous MCTs: associations with spay/neuter status, breed, body size, and phylogenetic cluster. J Am Anim Hosp Assoc; 2011 May-Jun;47(3):210-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Certain breeds are known to be overrepresented among mast cell tumor (MCT) patients, but other risk factors have not been evaluated.
  • This study presents results from a case-control study of 252 dogs with grade 2 or grade 3 cutaneous MCT.
  • [MeSH-major] Breeding. Castration / veterinary. Dog Diseases / epidemiology. Mast-Cell Sarcoma / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Body Size / physiology. Case-Control Studies. Confidence Intervals. Dogs. Female. Male. Neoplasm Staging / veterinary. Odds Ratio. Retrospective Studies. Risk Factors. Species Specificity

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21498594.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


top


2. Definitions


3. Related RMF webpages


terms of use | advertising programs | contact us
© 2014 RecentMedicalFindings


Connect with the


RMF


audience;




Post your ad here!